Business Description
CNS Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US18978H5081
Share Class Description:
CNSP: Ordinary SharesTotal Employee Number:
8Description
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.72 | |||||
Equity-to-Asset | 0.02 | |||||
Debt-to-Equity | 3.27 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 95 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 58.63 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.02 | |||||
9-Day RSI | 68.63 | |||||
14-Day RSI | 61.7 | |||||
3-1 Month Momentum % | 124.31 | |||||
6-1 Month Momentum % | -17.68 | |||||
12-1 Month Momentum % | -55.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.89 | |||||
Quick Ratio | 0.89 | |||||
Cash Ratio | 0.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -76.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -213.55 | |||||
ROA % | -154.36 | |||||
ROIC % | -2362.56 | |||||
3-Year ROIIC % | 1469.39 | |||||
ROC (Joel Greenblatt) % | -10307.26 | |||||
ROCE % | -213.37 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 60 | |||||
Price-to-Tangible-Book | 60 | |||||
EV-to-EBIT | -0.31 | |||||
EV-to-EBITDA | -0.31 | |||||
EV-to-FCF | -0.34 | |||||
Earnings Yield (Greenblatt) % | -322.58 | |||||
FCF Yield % | -192.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNSP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CNS Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -29.63 | ||
| Beta | 2.2409 | ||
| 3-Year Sharpe Ratio | -1.12 | ||
| 3-Year Sortino Ratio | -1.42 | ||
| Volatility % | 168.41 | ||
| 14-Day RSI | 61.7 | ||
| 14-Day ATR ($) | 0.448574 | ||
| 20-Day SMA ($) | 4.62234 | ||
| 12-1 Month Momentum % | -55.35 | ||
| 52-Week Range ($) | 1.9 - 11.388 | ||
| Shares Outstanding (Mil) | 1.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CNS Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CNS Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-17 12:00 | In 132 days | ||
| Third quarter earnings results for 2026 | 2026-11-17 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 36 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 5.01 (-5.47%) | ||
| Annual report for 2025 | 2026-03-31 | 2.27 (-12.02%) | ||
| General meeting for 2025 | 2025-11-17 12:00 | 6.90 (+14.24%) | ||
| Third quarter earnings results for 2025 | 2025-11-17 | 6.90 (+14.24%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 07:00 | 6.19 (+0.16%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 6.79 (+3.03%) | ||
| 0.0833333:1 Stock Split | 2025-07-22 | 8.94 (-3.47%) |
Show
Entries
CNS Pharmaceuticals Inc Frequently Asked Questions
What is CNS Pharmaceuticals Inc(CNSP)'s stock price today?
The current price of CNSP is $5.40. The 52 week high of CNSP is $11.39 and 52 week low is $1.90.
When is next earnings date of CNS Pharmaceuticals Inc(CNSP)?
The next earnings date of CNS Pharmaceuticals Inc(CNSP) is 2026-08-14 Est..
Does CNS Pharmaceuticals Inc(CNSP) pay dividends? If so, how much?
CNS Pharmaceuticals Inc(CNSP) does not pay dividend.
Guru Commentaries on NAS:CNSP
No articles.
Press Release
Articles on CNS Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers